Streetwise Reports' Article Archives — Current Month (20)
Biotech Co. Finds Massive Physiological Screening Breakthrough (04/29/2026)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) files patents for novel voice-biomarker intoxication detection, targeting applications in mining and aviation.
California Biopharma Co. Uncovers Massive Oncology Breakthrough (04/28/2026)
Nurix Therapeutics Inc. (NRIX:NASDAQ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential.
New York Healthcare Technology Co. Discovers Scalable Behavioral Health Breakthrough (04/28/2026)
DarioHealth Corp.'s (DRIO:NASDAQ) study showed measurable workplace productivity and cognitive function improvements in 1,254 users within weeks, boosting growth potential.
Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug (04/28/2026)
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) drug produced sustained neurologic and functional gains in chronic tetraplegia, positioning it for pivotal Phase 3 development.
Brisbane Biotech Showcases Degrader Pipeline Advantages at AACR (04/27/2026)
Nurix Therapeutics (NASDAQ: NRIX) recently showcased AACR presentations that highlighted the mechanistic superiority of the company's protein degrader platform and preclinical data across key pipeline assets, NX-1607, NRX-4972.
AI-Designed Cancer Drug Shows In Vivo Results, Brain Penetration (04/24/2026)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported new preclinical data across two oncology programs at the AACR Annual Meeting, including ATR-mTOR inhibitor efficacy and kt-3283 formulation progress.
CleanTech Co. Secures US$1.2M Mineral Processing Contract in Western US (04/23/2026)
BioLargo Inc. (BLGO:OTCQX) says a subsidiary has secured a US$1.2 million contract to design of a pilot-scale facility to reuse legacy mine waste in the Western U.S. One expert says the company has multiple catalysts approaching.
Asceniv Growth, Margin Expansion, and Pipeline Optionality Drive Price Target (04/23/2026)
Canaccord Genuity initiates coverage of ADMA Biologics Inc. (ADMA:NASDAQ), citing Asceniv's differentiated hyperimmune IVIG profile, accelerating margins from yield enhancement, and an underappreciated pipeline.
Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028 (04/20/2026)
MeiraGTx Holdings plc. (MGTX:NASDAQ) reported three-year durability data for AAV-hAQP1 in radiation-induced xerostomia, the reacquisition of filing-ready XLRP asset bota-vec from Johnson & Johnson, and a US$100M, according to an H.C. Wainwright research note.
Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone (04/20/2026)
MeiraGTx Holdings Plc (MGTX:NASDAQ) reports 3-year gene therapy results, secures US$100M funding, and advances late-stage pipeline, signaling major commercial potential.
Massachusetts Biotech Co. Faces Major Melanoma Drug Setback (04/14/2026)
Replimune Group Inc.'s (REPL:NASDAQ) RP1 melanoma therapy hits FDA rejection, raising uncertainty around approval timelines and future market potential.
Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics (04/13/2026)
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening.
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA (04/13/2026)
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry (04/09/2026)
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.
Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion (04/08/2026)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial (04/07/2026)
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.
California Biotech Co. Advances Depression Drug Breakthrough (04/07/2026)
Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.
Name Change, Share Consolidation, and US Clinic Strategy Signal Shift Toward Alzheimer's Diagnostics (04/06/2026)
Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) plans to rebrand to Grey Matters Health Inc. while advancing its Alzheimer's diagnostic strategy and U.S. clinic rollout.
Philly Biotech Co. Develops High-Potential Autoimmune Therapy Breakthrough (04/02/2026)
Cabaletta Bio Inc. (CABA:NASDAQ) pushes rese-cel CAR T program forward with strong clinical momentum, production scalability, and analyst-backed upside potential.
The World's First AI Voice Detection For Drugs & Alcohol With Charts That Beckon Investors To Buy (04/01/2026)
Technical Analyst Stewart Thomson explains why he thinks MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is a Speculative Buy.
More Archives
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
